| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3850603 | American Journal of Kidney Diseases | 2009 | 4 Pages |
Abstract
Deferasirox is an innovative iron-chelating treatment. However, preliminary data have suggested that kidney toxicity may be a major issue in the management of patients receiving this drug. We report a case of Fanconi syndrome associated with acute renal insufficiency in a patient receiving deferasirox. The latter has to be added to the expanding list of drugs that may induce Fanconi syndrome. Careful monitoring of kidney function and markers of proximal tubular injury are mandatory in patients undergoing treatment with deferasirox.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Cédric MD, Fadi MD, Jean-Antoine MD, Richard MD, Moglie MD,